New directions for protease inhibitors directed drug discovery

34Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Proteases play crucial roles in various biological processes, and their activities are essential for all living organisms—from viruses to humans. Since their functions are closely associated with many pathogenic mechanisms, their inhibitors or activators are important molecular targets for developing treatments for various diseases. Here, we describe drugs/drug candidates that target proteases, such as malarial plasmepsins, β-secretase, virus proteases, and dipeptidyl peptidase-4. Previously, we reported inhibitors of aspartic proteases, such as renin, human immunodeficiency virus type 1 protease, human T-lymphotropic virus type I protease, plasmepsins, and β-secretase, as drug candidates for hypertension, adult T-cell leukaemia, human T-lymphotropic virus type I-associated myelopathy, malaria, and Alzheimer's disease. Our inhibitors are also described in this review article as examples of drugs that target proteases. © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 563–579, 2016.

Cite

CITATION STYLE

APA

Hamada, Y., & Kiso, Y. (2016, November 4). New directions for protease inhibitors directed drug discovery. Biopolymers. John Wiley and Sons Inc. https://doi.org/10.1002/bip.22780

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free